TORONTO,
June 16, 2014 /PRNewswire/ - Lorus
Therapeutics Inc. (TSX: LOR) today announced that William G. Rice, Ph.D., Chairman and Chief
Executive Officer, will present at the 2014 Bloom Burton & Co.
Healthcare Investor Conference on Wednesday,
June 18, 2014, at 10:30 a.m.
ET at the Toronto Board of
Trade in Toronto. Dr. Rice will
provide a corporate overview of the Company's strategic direction
including plans to develop Lorus' lead clinical agent LOR-253 for
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and
other hematologic malignancies.
About Lorus
Lorus is a clinical-stage biotechnology company with a commitment
to discovering and developing targeted therapies addressing unmet
medical needs in oncology. We aim to develop therapeutics focused
on novel cellular targets on the leading edge of cancer research
coupled to companion diagnostics to identify the optimal patient
population for our products. Our pipeline of cancer drug candidates
includes small molecule products and immunotherapies providing
additive or synergistic efficacy without leading to overlapping
toxicities with existing anti-cancer regimens, facilitating the
adoption of doublet or possibly triplet therapies. Lorus
Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol
LOR.
Forward Looking Statements
This press release contains forward-looking statements within the
meaning of Canadian and U.S. securities laws. Such statements
include, but are not limited to, statements relating to: our
ability to obtain financing or partnerships, the establishment of
corporate alliances, our ability to maintain current and future
corporate alliances, our ability to fund or reach developmental
milestones, Lorus' plans, objectives, expectations and intentions
and other statements including words such as "continue", "expect",
"intend", "will", "should", "would", "may", and other similar
expressions. Such statements reflect our current views with respect
to future events and are subject to risks and uncertainties and are
necessarily based upon a number of estimates and assumptions that,
while considered reasonable by us are inherently subject to
significant business, economic, competitive, political and social
uncertainties and contingencies. Many factors could cause our
actual results, performance or achievements to be materially
different from any future results, performance or achievements
described in this press release. Such expressed or implied forward
looking statements could include, among others: our ability to
obtain the capital required for research and operations; the
inherent risks in early stage drug development including
demonstrating efficacy; development time/cost and the regulatory
approval process; the progress of our clinical trials; our ability
to find and enter into agreements with potential partners; our
ability to attract and retain key personnel; changing market
conditions; and other risks detailed from time-to-time in our
ongoing quarterly filings, annual information forms, annual reports
and annual filings with Canadian securities regulators and the
United States Securities and Exchange Commission.
Should one or more of these risks or
uncertainties materialize, or should the assumptions set out in the
section entitled "Risk Factors" in our filings with Canadian
securities regulators and the United States Securities and Exchange
Commission underlying those forward-looking statements prove
incorrect, actual results may vary materially from those described
herein. These forward-looking statements are made as of the date of
this press release and we do not intend, and do not assume any
obligation, to update these forward-looking statements, except as
required by law. We cannot assure you that such statements will
prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements.
Investors are cautioned that forward-looking statements are not
guarantees of future performance and accordingly investors are
cautioned not to put undue reliance on forward-looking statements
due to the inherent uncertainty therein.
SOURCE Lorus Therapeutics Inc.